Gabelli Funds’s Biolase, Inc. BIOL Stock Holding History

Gabelli Funds’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-8	Closed	-$38K	–	1161
2018 Q1	$38K	Hold	8	–	–	﹤0.01%	1141
2017 Q4	$40K	Buy	8 +2	+33%	+$14.1K	﹤0.01%	1111
2017 Q3	$42K	Hold	6	–	–	﹤0.01%	1117
2017 Q2	$68K	Buy	6 +3	+100%	+$44.5K	﹤0.01%	1124
2017 Q1	$58K	Hold	3	–	–	﹤0.01%	1130
2016 Q4	$60K	Hold	3	–	–	﹤0.01%	1135
2016 Q3	$75K	Hold	3	–	–	﹤0.01%	1150
2016 Q2	$50K	Hold	3	–	–	﹤0.01%	1158
2016 Q1	$56K	Hold	3	–	–	﹤0.01%	1127
2015 Q4	$36K	Hold	3	–	–	﹤0.01%	1133
2015 Q3	$39K	Sell	3 -1	-25%	-$18.6K	﹤0.01%	1088
2015 Q2	$79K	Hold	4	–	–	﹤0.01%	1081
2015 Q1	$92K	Hold	4	–	–	﹤0.01%	1065
2014 Q4	$120K	Hold	4	–	–	﹤0.01%	1073
2014 Q3	$114K	Hold	4	–	–	﹤0.01%	1077
2014 Q2	$100K	Hold	4	–	–	﹤0.01%	1064
2014 Q1	$110K	Hold	4	–	–	﹤0.01%	1044
2013 Q4	$129K	Hold	4	–	–	﹤0.01%	1034
2013 Q3	$86K	Hold	4	–	–	﹤0.01%	1032
2013 Q2	$166K	Buy	+4	New	+$224K	﹤0.01%	1009

Other funds holding BIOL

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PCM

Princeton Capital Management Red Bank, New Jersey $367M AUM 45.24% 1-Year Est. Return

Teton Advisors Rye, New York $142M AUM 42.07% 1-Year Est. Return

GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return

Gabelli Funds's BIOL Position: Q2 2018 in Review

Gabelli Funds sold out of Biolase, Inc. (BIOL) in Q2 2018, closing a stake of 8 shares — an estimated $38K sold.

Gabelli Funds first reported a position in BIOL in Q2 2013 and held it in 20 quarters. The position peaked at $166K in Q2 2013. 18 funds tracked by Wall St. Rank hold BIOL as of Q2 2018.

Gabelli Funds reported no remaining Biolase, Inc. position as of Q2 2018 after selling out during the quarter.
Gabelli Funds sold 8 Biolase, Inc. shares in Q2 2018, an estimated $38K.
Gabelli Funds first reported a position in Biolase, Inc. in Q2 2013 and held it in 20 quarters.
Gabelli Funds's Biolase, Inc. position peaked at $166K in Q2 2013.
18 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2018.

Based on Gabelli Funds's 13F filing for Q2 2018, filed 10 Aug 2018.